Answers are grounded in this paper and cite their sources.
Observes reduced QRS voltage and left ventricular mass after agalsidase alfa therapy in a female patient with Fabry disease, suggesting electrocardiography tracks treatment response.
Fabry disease is an X-linked lysosomal storage disorder caused by defective enzyme activity of α-galactosidase A and treated with enzyme replacement therapy (ERT) with recombinant α-galactosidase. ERT reduces left ventricular mass assessed by echocardiography or magnetic resonance imaging. However, electrocardiogram changes during ERT have not been fully elucidated. In the present case, ERT with agalsidase alfa for 4 years decreased QRS voltage and negative T depth along with a reduction of left ventricular mass and wall thickness and improvement of symptoms in a female patient with Fabry disease. Long-term observation of electrocardiogram changes might be useful for determining the efficacy of ERT in this case.
No takes yet. Share an insight, caveat, or question.
Nakamura et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: